Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

BioMarin Pharmaceutical. 2016. BioMarin provides encouraging preliminary data on first 8 patients in hemophilia A gene therapy program. Available at: http://investors.bmrn.com/releasedetail.cfm?releaseid=965945 (accessed May 4, 2016).

Sarepta Therapeutics. 2016. Sarepta issues statement on advisory committee outcome for use of eteplirsen in the treatment of Duchenne muscular dystrophy. Available at: http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2161215 (accessed May 9, 2016).

Pollack

. 2016. Advisers to FDA vote against Duchenne muscular dystrophy drug. The New York Times, April 25. Available at: www.nytimes.com/2016/04/26/business/muscular-dystrophy-drug-fda-sarepta-eteplirsen.html (accessed May 9, 2016).

CureDuchenne. 2016. CureDuchenne responds to FDA advisory committee's recommendation against approval of eteplirsen for Duchenne muscular dystrophy. Available at: www.cureduchenne.org/press/cureduchenne-responds-to-fda-1.html (accessed May 9, 2016).

GlaxoSmithKline. 2016. GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID. Available at: www.gsk.com/en-gb/media/press-releases/2016/gsk-receives-positive-chmp-opinion-in-europe-for-strimvelis-the-first-gene-therapy-to-treat-very-rare-disease-ada-scid/ (accessed May 2, 2016).

U.S. Securities and Exchange Commission. 2016. Re: GenSight Biologics S.A., application for withdrawal of (i) Registration Statement on Form F-1 (File No. 333-205539) and (ii) Registration Statement on Form 8-A (File No. 001-37618). Available at: www.sec.gov/Archives/edgar/data/1641634/000119312516541188/d160136drw.htm (accessed May 2, 2016).

Genetic Engineering & Biotechnology News. 2016. UPDATE: Investors wary as Clinton takes aim at drug prices. Available at: www.genengnews.com/gen-news-highlights/investors-wary-as-clinton-takes-aim-at-drug-prices/81251760/ (accessed May 2, 2016).

U.S. National Institutes of Health. 2016. Statement on review of NIH sterile production facilities. Available at: https://www.nih.gov/news-events/news-releases/statement-review-nih-sterile-production-facilities (accessed April 19, 2016).

Kite Pharma. 2016. Kite Pharma announces review of National Cancer Institute's manufacturing facilities. Available at: http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=965432 (accessed May 9, 2016).

10.

Lion Biotechnologies. 2016. Lion Biotechnologies manufacturing capabilities and research programs unaffected by review of National Cancer Institute's manufacturing facilities. Available at: http://ir.lbio.com/press-releases/detail/70/lion-biotechnologies-manufacturing-capabilities-and (accessed May 9, 2016).

11.

U.S. National Institutes of Health. 2016. The Clinical Center working group report to the advisory committee to the director, NIH: Reducing risk and promoting patient safety for NIH intramural clinical research, final report. Available at: http://acd.od.nih.gov/Red_Team_final_report_4262016.pdf (accessed May 9, 2016).

12.

Juno Therapeutics and WuXi AppTec. 2016. Juno Therapeutics and WuXi AppTec announce new company to develop novel cell-based cancer immunotherapies in China. Available at: https://www.wuxiapptec.com/press/detail/318/18.html (accessed May 2, 2016).